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ABSTRACT
Introduction. The incidence of gastrointestinal (GI) can-
cer is rising and most patients with GI malignancies are
discussed by a multidisciplinary team (MDT). We per-
formed a systematic review to assess whether MDTs for
patients with GI malignancies can correctly change diag-
nosis, tumor stage and subsequent treatment plan, and
whether the treatment plan was implemented.
Methods. We performed a systematic review according to
the Preferred Reporting Items for Systematic Reviews and
Meta-Analyses guidelines. We conducted a search of the
PubMed, MEDLINE and EMBASE electronic databases,
and included studies relating to adults with a GI malig-
nancy discussed by an MDT prior to the start of treatment
which described a change of initial diagnosis, stage or
treatment plan. Two researchers independently evaluated
all retrieved titles and abstracts from the abovementioned
databases.
Results. Overall, 16 studies were included; the study
quality was rated as fair. Four studies reported that MDTs
changed the diagnoses formulated by individual physicians
in 18.4–26.9% of evaluated cases; two studies reported that
MDTs formulated an accurate diagnosis in 89 and 93.5% of
evaluated cases, respectively; nine studies described that
the treatment plan was altered in 23.0–41.7% of evaluated
cases; and four studies found that MDT decisions were
implemented in 90–100% of evaluated cases. The reasons
for altering a treatment plan included the patient’s wishes,
and comorbidities.
Conclusions. MDT meetings for patients with a GI
malignancy are responsible for changes in diagnoses and
management in a significant number of patients. Treatment
plans formulated by MDTs are implemented in 90–100%
of discussed patients. All patients with a GI malignancy
should be discussed by an MDT.
The incidence of gastrointestinal (GI) malignancies is
rising, and, in The Netherlands, the incidence of colorectal
carcinoma is expected to increase by 40% in 2020.1 To
ensure the best care for every patient, a multidisciplinary
approach seems important. The multidisciplinary approach
to patients with cancer has been described in the literature
since 19752; however, multidisciplinary teams (MDTs)
have only been in effect since the late 1990s. Since MDTs
likely require an increase in available time and recourses,
their existence has been questioned.3,4
In the last two decades, this multidisciplinary approach,
often implemented as MDTs, has become routine in our
healthcare system. An MDT consists of healthcare spe-
cialists from different medical specialties working together
for specific diseases.5–7 These teams meet at periodic
intervals (i.e., daily or weekly) to discuss and diagnose
patients with complex diseases such as cancer, and subse-
quently formulate a treatment plan according to the current
guidelines.5–8 In this systematic review, this will be refer-
red to as the MDT meeting (MDTM). Several articles
relating to various oncological diagnoses show valuable
insights into the effectiveness of MDTMs.5,8–14 For
instance, patients discussed in an MDTM have been shown
to be more satisfied and more often receive a correct
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diagnosis and treatment plan according to guidelines.5,9–14
Although this suggests that MDTs are able to improve
patient care, improved patient outcomes, such as survival,
have not yet been established.8
Patients with GI malignancies comprise a large portion
of all cancer patients. Often, gastroenterologists and sur-
geons specialized in GI malignancies are interested in more
than one tumor type. Therefore, we felt it was important to
evaluate patients with GI malignancies as one group. The
aim of this systematic review was to assess whether there is
scientific evidence in the literature that discussion in a
multidisciplinary GI cancer team meeting influences the
diagnosis and treatment plan for patients with GI malig-
nancies. We specifically focused on whether an MDT can
correctly change diagnosis and tumor stage. Additionally,
this review aimed to evaluate whether the subsequent
treatment plan was also changed and whether a treatment
plan formulated by an MDT was implemented.
METHODS
This systematic review was performed according to the
Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) guidelines.15
Search Strategy and Eligibility Criteria
A systematic literature search was performed in the
PubMed, MEDLINE and EMBASE electronic databases.
The free text and Medical Subject Heading search terms
used were variations of ‘multidisciplinary’ and ‘team’,
‘correct diagnosis’, ‘changes in diagnosis’, ‘survival’,
‘guidelines adherence’, and ‘gastrointestinal neoplasm’
(the detailed search is documented in Appendix). No lan-
guage or time restrictions were set, and references of lists
of the included articles were hand searched. The last search
was run on 30 November 2016.
Articles were included when the following criteria were
fulfilled: studies that relate to adults with a GI malignancy
and describe a change in initial diagnosis, stage, or treat-
ment. All study types were included, with the exception of
case series due to the high potential bias in this study
design. Review articles were assessed to ensure the articles
evaluated were found in our search. Thereafter, review
articles were excluded. Two researchers (YB and SB)
individually applied these criteria to all retrieved titles and
abstracts. Any disagreements were first discussed between
the two researchers and, if no agreement could be reached,
an independent investigator with expert knowledge of the
field was contacted (KT). Reference lists of included arti-
cles were screened to ensure no relevant articles had been
missed.
Data Extraction
A data extraction sheet was developed for this study,
based on information provided by the Centre for Reviews
and Dissemination.16 Two researchers (YB and SB) inde-
pendently extracted the data, and disagreement was
resolved by discussion between the two researchers. Due to
the diversity of the data, summary measures or meta-
analyses were not appropriate; instead, a narrative
description of the findings is reported.
Quality Assessment
Quality assessment of the included papers was per-
formed with two separate tools created and validated by the
National Institutes of Health (NIH). Before–after studies
were assessed using the ‘Quality Assessment Tool for
Before–After (Pre–Post) Studies With No Control
Group’.17 With this tool, 12 different criteria could be
evaluated and rated with ‘yes’, ‘no’, ‘could not determine’
(CD), and ‘not applicable’ (NA). Cohort studies were
evaluated using the ‘Quality Assessment Tool for Obser-
vational Cohort and Cross-Sectional Studies’.17 This tool
had a 14-criteria checklist and could be rated identically to
the before–after studies. Two researchers (YB and SB),
independently of each other, classified the included papers
as ‘poor’, ‘fair’, or ‘good’ using the aforementioned tools.
Any disagreement was initially discussed between these
two researchers and, if no agreement could be reached, a
third reviewer was contacted to make the decision (KT).
The same two researches (YB and SB) also indepen-
dently assessed the risk of bias and, if no agreement could
be reached, the third reviewer was consulted (KT). The risk
of bias was assessed for both cohort and before–after
studies using a single tool ‘To Assess the Risk of Bias in
Cohort Studies’, validated by the Cochrane Institute. With
this tool, eight criteria could be rated on a four-item scale:
definitely yes (low risk of bias), probably yes, probably no,
and definitely no (high risk of bias). Bias was assessed at
outcome level.
RESULTS
A total of 2400 articles were retrieved (Fig. 1). The titles
and abstracts of these articles were screened to evaluate
whether the inclusion criteria were met. Sixteen studies
met the inclusion criteria and were the basis for this sys-
tematic review.13,18–32 Screening the references of the
included studies produced no new articles. Study charac-
teristics are described in Table 1. In total, 8018 patients
were discussed in 16 articles. Of these patients, 48.5% had
an esophageal or gastric malignancy, 25.6% had a col-
orectal malignancy, 16.3% had a pancreatic or biliary
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malignancy, 9.1% had a liver malignancy or neuroen-
docrine tumor, and 0.5% had other malignancies.
Quality Assessment
All cohort articles and before–after studies were clas-
sified as fair, as evaluated using the quality assessment
tools of the NIH (Tables 2, 3). All studies scored a mod-
erate risk of bias, using the bias assessment tool validated
by the Cochrane Institute (Table 4).
Diagnoses and Staging
Eight studies described diagnoses for patients with GI
malignancies, formulated by an MDT.13,22,24,25,27,30–32 The
study by Basta et al. described whether changes in the
initial diagnosis or stage were validated with either
pathology or follow-up.31 In this study (various GI
malignancies, n = 550), no diagnosis or stage was changed
after validation by pathology or after follow-up.31 Six
studies investigated diagnoses formulated by the MDT, of
which five described that a different diagnosis was for-
mulated by the MDT compared with the diagnosis
formulated by the referring physician.22,24,30–32 Four of
these studies found that 18.4–22.2% of the diagnoses were
changed.22,24,31,32 Three studies regarding various GI
malignancies (n = 551), pancreatic cancer (n = 203), and
liver cancer (n = 343) described a proportion of patients
who eventually had a benign diagnosis (6.0, 10.5, and
30.8%, respectively). The study by Meguid et al. (various
GI malignancies, n = 1747) did not describe whether a
proportion of patients received a benign diagnosis after
evaluation by the MDT.32 Furthermore, the study by Fer-
nando and colleagues (colon cancer, n = 459) investigated
these changes in a subset (n = 456/459) of their patient
population. They described that in only 4% (n = 20) of
patients discussed, the clinical stage was changed.30
The four other studies regarding diagnoses formulated
by the MDT described whether the diagnosis formulated by
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FIG. 1 Literature search according to the PRISMA guidelines. 1Excluded because titles and abstracts did not meet the inclusion criteria.
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551 21.8% Change in referral dx, of
which both stage and dx were
changed for 3.2%, stage alone
was changed for 4.9%, and dx
alone was changed for 12.2%.
6% were diagnosed with
benign disease. Different
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To assess the impact of an MDT
on implementing an MRI-
based preoperative treatment
strategy
Rectal cancer 298 For patients discussed by the
MDT, the CRM? rate was 8
versus 26% CRM? rate for
patients NOT discussed by
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An initial management plan was
determined in 94 patients,
which was changed in 22
(23%) patients after
discussion by the MDT. The
MDT changed the clinical
staging in 20 (4%) cases.
Patients with colon cancers
are less often discussed in an
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Esophageal cancer Pre-MDT: 117
Post-MDT:138
97% of patients received a
complete staging versus 67%
pre-MDT (p\ 0.0001). In the
post-MDT group, 9%
endoscopic resection versus
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1747 26.9% Change in dx, 20.5%
radiographic or endoscopic,
resulting in stage change,
4.9% radiographic
evaluations that resulted in
change in clinical dx, 1.9%
change in path review, 6.4%
incidental findings, and








To assess change in treatment
plan from pre- and post-MDT
discussion
GI malignancy Upper GI: 115
Lower GI: 34
36% of initial management plans
were changed by the MDT, of
which the original stated plan
was preceded by additional
treatment for 15, and the
change was ‘major’ for 38












To evaluate the impact of an
MDT on the advice of patients
compared with prior advice
Pancreatic cancer 203 dx for 38 patients was altered by
MDT: 3 patients turned out to
be irresectable, 26 were
metastasized, 4 patients had
benign diseases, and 5 turned







To prospectively analyze the
evolution in staging and
treatment plans and
subsequent level of adherence
Esophageal cancer 185 Primary care provider treatment
plans were changed for 48
(26%) patients. Diagnostic
procedures (staging) were
altered for 30 patients (16%).








To assess the quality of the
MDT, the effect of the
MDT on the original
treatment plan, compliance
with the MDT treatment plan,
and the clinical outcomes
Rectal cancer 42 A change in treatment plan
occurred in 29% (n = 12) of
patients, of which five had
their treatment changed
because of reinterpretation of
the MRI, and six because of
tumor factors. One patient
had his treatment changed












To determine the effect of an
MDT on clinical decision
making
Upper GI 171 34.5% (n = 87) of initial
treatment plans changed after
discussion by the MDT; 8
changed from curative to
palliative, and 2 changed
from palliative to curative.
For 31, a different treatment
modality was preferred, and,
for 29, a more extensive
workup was needed. For two
cases, a different treatment








To analyze if MDT decisions are
implemented and what factors
influence this




Of the 20 decisions (10%) that
changed after the meeting, the
most common reason was
comorbidity (n = 16). Seven
decisions changed due to
patient wishes and two
changed in light of new
clinical information. One was







To assess the effect of MDTs on
the management of patients
Colorectal cancer Pre-MDT: 297
Post-MDT:298
Pre-MDT, 41.1% of patients
underwent CT staging versus
81.3% post-MDT
(p\ 0.001). In the pre-MDT
group, 26.7% had liver
metastasis 6 months after dx
versus 9.3% post-MDT
(p\ 0.05). MDTs increased
5-year survival from 62.4 to
79.1% (p = 0.015)
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(gastric or esophageal cancer, n = 118), it was demon-
strated that in 89% of patients discussed in an MDTM, a
correct diagnosis was formulated.13 Basta and colleagues
found that the MDT accurately diagnosed 93.5% of eval-
uated cases.31 In both studies, the diagnoses were validated
by pathology or follow-up. The two other studies described
the extent to which the discussion during the MDTM
influenced staging.25,27 The study by Ye et al. (colorectal
carcinoma, n = 595) found that after introduction of the
MDTM, more patients underwent computed tomography
(CT) examination before operation (55.7 vs. 30.0%). Ye
et al. found fewer liver metastases in the post-MDT group,
6 months after resection,27 while the study by Freeman
et al. (esophageal cancer, n = 255) found that patients
discussed after the implementation of the MDTMs more
often received a complete staging evaluation (97 vs.
67%).25 Complete staging evaluation was defined as ‘‘a
minimum of CT and PET scans, esophagogastroduo-
denoscopy, bronchoscopy, complete blood count,
electrolyte profile, and endoscopic esophageal ultrasonog-
raphy, biopsy confirmation of suspected metastatic disease
and further evaluation of any specific symptoms’’.25
Treatment Plan
Thirteen studies described treatment plans formulated
by an MDT,18–25,28–32 nine of which described whether the
treatment plan formulated by the referring physician was
changed after discussion by the MDT.18,21–24,28–30,32 These
studies reported on 42–1747 patients and found that
23.0–41.7% of the treatment plans formulated by the
referring physician were changed after discussion by the
MDT.18,21–24,28–30 Changes in the treatment plan could be
divided into minor and major changes: minor changes were
defined as additions to the originally stated treatment plan
and occurred in 28.0–58.0% of the alterations made by the
MDT; major changes encompassed an alteration in treat-
ment modality and occurred in 41.5–72.0% of the changes
formulated by the MDTs.18,21,22 Treatment plans were
most often changed after an alteration of the initial diag-
nosis or stage.22,24,28 In the study by Pawlik et al., 77% of
changes in treatment were led by a change in diagnosis or
stage, while Snelgrove and colleagues found that 100% of
changes in treatment were due to changes in diagnosis.22,28
In the study by Zhang et al., only 33% of changes in
treatment were due to a change in diagnosis or stage.24 In
six studies the authors did not report why the initial treat-
ment plan formulated by the referring physician was
changed after discussion at an MDTM.18,21,23,29,30,32
The three remaining studies focused on adherence to
guidelines by an MDT19,20,25; Dickinson et al. (pancreatic
body cancer, n = 31), observed that more patients received
chemotherapy after being discussed at an MDTM (43 vs.
25%),20 while Burton et al. (rectal cancer, n = 298) used
the circumferential resection margin (CRM) as an indicator
for the quality of their MDT.19 After implementation of
mandatory preoperative magnetic resonance imaging
(MRI) and discussion at the MDTM, there were signifi-
cantly less positive CRMs: 1% after implementation of the
MDTM versus 26% before implementation.19 Patients not
discussed at the MDTM did not receive preoperative
neoadjuvant treatment. In the third study, Freeman et al.
(esophageal cancer, n = 255) found that for patients dis-
cussed at an MDTM, the treatment plan more often
adhered to national guidelines: 98 versus 83%.25
Implementation of the Treatment Plan
Two articles on patients with colorectal carcinoma
(n = 185 and 201), two articles on esophageal and gastric
cancer (n = 42 and 2450), and one article on various GI

















Liver cancer 343 For 26 patients, diagnoses were
altered, 8 from malignant/
indeterminate to benign, 5
from benign to malignant.
Management plans were
initially formulated for 168
patients, of which 70 were
changed; from irresectable to
resectable for 5 patients and
vice versa for 4 patients
MDT multidisciplinary team, NR not reported, MDLC multidisciplinary liver clinic, GI gastrointestinal, MRI magnetic resonance imaging, HCC hepatocellular
carcinoma, CRC colorectal carcinoma, NET neuroendocrine tumor, dx diagnosis, CRM circumferential resection margin, CT computed tomography, Major change
changes between liver-directed therapies, chemotherapy, radiation therapy, type of surgery, ablative therapies, observation and endoscopic procedures21
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decisions formulated by the MDT were actually imple-
mented.18,26,28,29,31 The implementation rate ranged from 90
to 100%. The reasons for not following MDT advice were
comorbidity (45%) and patient preferences (35%), followed
by new clinical information (10%), different opinion of the
treating physician (5%), and unknown (5%).26,29


























Clear aim Yes Yes Yes Yes Yes Yes Yes No Yes Yes No Yes
Population defined Yes Yes Yes Yes Yes NR Yes Yes Yes Yes Yes Yes
Participation rate of
[50%




Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Sample size
justification




No No No No No NA No No No Yes Yes No
Sufficient time frame Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Different levels of
exposure examined
NA NA NA NA NA NA NA NA NA NA NA NA
Exposure measures
defined
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Exposures assessed[1 Yes No No No No No No No No No No No
Outcome measures
clear
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes No Yes
Assessors blinded No No No No No No No No No No No No
Loss to follow-up
\20%




Yes CD No No No Yes No CD No CD Yes No
CD could not determine, NR not reported, NA not applicable
TABLE 3 Quality assessment before–after studies
Bumm et al.18 Dickinson et al.20 Freeman et al.25 Pawlik et al.22
Objective clearly stated Yes Yes No Yes
Eligibility criteria specified Yes Yes Yes Yes
Participants’ representative Yes Yes Yes Yes
All eligible participants enrolled Yes Yes Yes Yes
Sample size sufficiently large NR NR NR NR
Intervention clearly described Yes Yes Yes Yes
Outcome measures specified No Yes No Yes
Assessors blinded No No No No
Follow-up CD CD CD NR
Statistical methods NA Yes Yes NA
Outcome measures taken multiple times before and after intervention No No No No
Statistical analysis for group to individual effect NA NA NA NA
CD could not determine, NR not reported, NA not applicable
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DISCUSSION
This systematic review focuses on the changes in diagnosis
and treatment plan formulated at the MDTM for patients with
a GI malignancy. Changes in diagnosis occurred for
18.4–26.9% of the evaluated patients, and changes in treat-
ment occurred in 23.0–41.7% of the evaluated patients. To
our knowledge, this is the first systematic review to assess
these outcomes in the field of GI oncology.
Discussion of patients in an MDTM has many advan-
tages. Different medical specialists convene to discuss
diagnoses, view radiographic imaging, and review pathol-
ogy. Additionally, an MDTM facilitates exchanging
knowledge and ensures a more extensive understanding
regarding the treatment possibilities of other medical spe-
cialties. Both diagnostic capabilities and therapeutic
options can be easily discussed to ensure the best treatment
for each individual patient.
For all patients, it is important to receive a correct
diagnosis and staging of the disease since this will lead to a
correct treatment plan. Patients discussed at an MDTM
seem to have more accurate diagnoses than patients diag-
nosed by a single physician. This statement is supported by
the observed changes made in diagnoses for patients dis-
cussed in an MDTM (18.4–26.9%). It is probable that team
members better adhere to diagnostic protocols and there-
fore formulate more accurate diagnoses.25,27 Although the
included studies show little evidence as to whether these
changes in diagnoses are accurate, both Basta et al. and
Davies et al. proved that diagnoses formulated at an
MDTM are often correct.13,31
We also found that discussion at an MDTM can lead to a
different treatment plan that better adheres to existing
guidelines; however, none of the authors of the included
studies described which guidelines were used at their
institute. Treatment plans for patients with a GI malig-
nancy formulated by an MDT are often implemented. The
major reasons for not implementing a treatment plan
included patient morbidity and patient preferences; it is
important to know the patient’s condition and wishes in
advance. There are several ways to ensure the patient’s
wishes and physical condition are taken into account. The
presence of a physician who has met the patient is one the
most influencing factors to ensure that due attention is paid
to this.31 Other ways of ensuring this also exist, i.e., nurses,
nurse practitioners, or psycho-oncologists can be employed
to ensure these aspects are incorporated into the decision-
making process. Additionally, the patient can be present at
the MDTM to ensure his wishes are taken into account
when formulating a treatment plan; however, the latter is
not often employed, which could be due to several reasons.
During MDTMs, medical terminology is often used. For
patients, this is generally difficult to understand and could
even be perceived as frightening.33 It is possible that
patients are not yet aware of their diagnosis at the time of
the MDTM. It is of course unacceptable to tell patients
their diagnosis within the 4 min timeframe usually used to
discuss patients during an MDT.31,33–35 Additionally, it





































































































































































Basta, 2016 1 1 1 1 1 2 1 1 fair
Bumm, 2007 1 1 1 1 1 4 1 1 fair
Burton, 2006 1 1 4 1 3 3 1 1 fair
Davies, 2006 1 1 2 1 1 2 1 2 fair
Dickinson, 2007 1 2 4 4 3 3 1 1 fair
Freeman, 2011 1 1 1 4 3 2 3 1 fair
Fernando, 2015 1 1 1 4 1 3 1 2 fair
Meguid, 2016 1 1 1 1 1 2 3 1 fair
Oxenberg, 2015 1 1 1 1 3 3 1 1 fair
Pawlik, 2008 1 1 1 1 3 2 1 1 fair
Schmidt, 2015 1 1 1 1 3 2 1 1 fair
Snelgrove, 2015 1 1 1 1 3 3 2 1 fair
van Hagen, 2013 1 1 1 1 3 2 2 1 fair
Wood, 2008 1 1 1 1 1 2 1 1 fair
Ye, 2012 1 2 1 1 3 2 1 1 fair
Zhang, 2013 1 1 1 1 3 3 1 1 fair
Bias assessed with the Cochrane tool to ‘‘Assess risk of bias in cohort
studies’’ (Appendix). Quality assessed with the quality assessment
tool for ‘‘Before–after studies’’ and ‘‘For observational cohort and
cross-sectional studies’’ from the National Heart, Lung, and Blood
Institute (Appendix)
1 indicates ‘definitely yes’ (low risk of bias), 2 indicates ‘probably
yes’, 3 indicates ‘probably no’, 4 indicates ‘definitely no’ (high risk of
bias)
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seems most healthcare providers do not wish to have
patients present during the MDTM.35
One of the strengths of this review is renewed attention
to a subject that has become integrated in our healthcare
system. Our systematic review corroborates the conception
that MDTMs positively contribute to modern healthcare.
This review also has some limitations. The group of
patients with GI malignancies is still fairly heterogeneous,
therefore a quantitative analysis, such as a meta-analysis,
was not possible. The types of studies included in this
review have all used study methodologies more prone to
bias and of lesser scientific quality, i.e. (retrospective)
cohort studies or before–after studies. This is common in
comparative studies assessing healthcare outcomes.6,11,36,37
We have found several definitions used to describe
MDTMs, however due to the wide variability in the defi-
nitions used in the literature, it is possible there are
definitions unknown to us. The different definitions used
for MDTs, as well as the differences in outcome measures,
further increase the difficulty of objectively studying the
effect of MDTs and MDTMs on healthcare; it is possible
relevant literature has been missed. No studies reported on
an MDT performing worse than a single physician,
although one study reported no difference,25 which could
mean MDTs actually ensure enhanced care is delivered, or
a publication bias was evident. In most studies, whether a
patient was discussed by an MDT was at the sole discretion
of the treating physician. Both of these can cause dis-
crepancies between the pre- and post-MDT groups. None
of the studies have taken into account changes in treatment
over time.
CONCLUSIONS
The majority of the reviewed studies found that MDTs
have definite advantages: better adherence to guidelines,
better diagnostics, and better adherence to formulated
treatment plans. These advantages seem to outweigh the
disadvantages, i.e., economic costs. To objectively com-
pare the advantages with the disadvantages, MDTs and
MDTMs should be more clearly defined. Additionally,
their outcome measures should also be defined. Studies and
reviews that show how MDTMs influence patient care and
work satisfaction are of the utmost importance. However,
in light of the presented evidence, we firmly believe in both
the benefit and durability of MDTMs; MDTs are here to
stay!
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